Biological and cytogenetic-molecular characteristics of AML patients in this study
| Patient ID . | Diagnosis . | Cytogenetics . | Molecular . | Age, y . | Sex . | Blasts, % . | Risk group . |
|---|---|---|---|---|---|---|---|
| 14011 | AML-M5 | 46, XY, inv(16) | Cbfb-MYH11 | 1 | M | 50 | FR |
| 14022 | AML | 46, XX | NPM1MUT, IDH1MUT | 20 | F | 92 | FR |
| 14030 | AML | 46, XY | NPM1MUT | 18 | M | 32 | FR |
| 14046 | AML-M3 | 46, XX t(15;17) | PML-RARa | 59 | F | 90 | FR |
| 14032 | AML | 46, XY | NPM1MUT | 80 | M | 49 | FR |
| 14096 | AML-M3 | 46, XY, t(15;17) | PML-RARa | 25 | M | 90 | FR |
| 14175 | AML-M4 | 46, XX, t(8;21) | AML1-ETO | 9 | F | 75 | FR |
| 14218 | AML | 46, XY | NPM1MUT | 62 | M | 25 | FR |
| 14182 | AML-M5 | 46, XY, inv(16) | Cbfb-MYH11 | 5 | M | 32 | FR |
| 14185 | AML-M5 | 46, XY, inv(16) | Cbfb-MYH11 | 8 | M | 77 | FR |
| 14008 | AML | 46, XY | — | 10 | M | 92 | IR |
| 14089 | AML | 46, XY | — | 77 | M | 45 | IR |
| 14088 | AML-M4 | 46, XX | — | 61 | F | 71 | IR |
| 14050 | AML-M4 | 46, XY | — | 86 | M | 50 | IR |
| 14113 | AML | 46, XY | — | 56 | M | 40 | IR |
| 14204 | AML | 46, XX | — | 82 | F | 71 | IR |
| 14137 | AML-M5 | 46, XY | — | 76 | M | 50 | IR |
| 14202 | AML-M5 | 46, XY | — | 47 | M | 54 | IR |
| 14119 | AML-M0/M1 | 46, XY | — | 9 | M | 86 | IR |
| 14048 | AML-M4 | 46, XX, t(9;11) | MLL-AF9 | 63 | F | 90 | HR |
| 14057 | AML-M5 | 46, XX | NPM1MUT, FLT3-ITDhi | 65 | F | 90 | HR |
| 14058 | AML-M1 | 46, XX | NPM1MUT, FLT3-ITDhi | 73 | F | 90 | HR |
| 14070 | AML-M1 | 46, XX, t(9;11) | MLL-AF9 | 77 | F | 80 | HR |
| 14085 | AML-M4 | 46, XY | NPM1MUT, FLT3-ITDhi, WT1MUT | 42 | M | 99 | HR |
| 14093 | AML-M4 | 46, XX | NPM1MUT, FLT3-ITDhi | 52 | F | 81 | HR |
| 14160 | AML-M5a | 47,XX,8,+i(8)(q10)x2,t(8;21),t(9;11) | MLL-AF9, ABL+, AML1-ETO, WT1MUT | 6 | F | 66 | HR |
| 14186 | AML-M5b | 46,XY,t(11;17) MLL (11q23)+ | MLL-RARa | 1 | M | 87 | HR |
| 14163 | AML | 46, XY | NPM1MUT, FLT3-ITDhi | 48 | M | 88 | HR |
| Patient ID . | Diagnosis . | Cytogenetics . | Molecular . | Age, y . | Sex . | Blasts, % . | Risk group . |
|---|---|---|---|---|---|---|---|
| 14011 | AML-M5 | 46, XY, inv(16) | Cbfb-MYH11 | 1 | M | 50 | FR |
| 14022 | AML | 46, XX | NPM1MUT, IDH1MUT | 20 | F | 92 | FR |
| 14030 | AML | 46, XY | NPM1MUT | 18 | M | 32 | FR |
| 14046 | AML-M3 | 46, XX t(15;17) | PML-RARa | 59 | F | 90 | FR |
| 14032 | AML | 46, XY | NPM1MUT | 80 | M | 49 | FR |
| 14096 | AML-M3 | 46, XY, t(15;17) | PML-RARa | 25 | M | 90 | FR |
| 14175 | AML-M4 | 46, XX, t(8;21) | AML1-ETO | 9 | F | 75 | FR |
| 14218 | AML | 46, XY | NPM1MUT | 62 | M | 25 | FR |
| 14182 | AML-M5 | 46, XY, inv(16) | Cbfb-MYH11 | 5 | M | 32 | FR |
| 14185 | AML-M5 | 46, XY, inv(16) | Cbfb-MYH11 | 8 | M | 77 | FR |
| 14008 | AML | 46, XY | — | 10 | M | 92 | IR |
| 14089 | AML | 46, XY | — | 77 | M | 45 | IR |
| 14088 | AML-M4 | 46, XX | — | 61 | F | 71 | IR |
| 14050 | AML-M4 | 46, XY | — | 86 | M | 50 | IR |
| 14113 | AML | 46, XY | — | 56 | M | 40 | IR |
| 14204 | AML | 46, XX | — | 82 | F | 71 | IR |
| 14137 | AML-M5 | 46, XY | — | 76 | M | 50 | IR |
| 14202 | AML-M5 | 46, XY | — | 47 | M | 54 | IR |
| 14119 | AML-M0/M1 | 46, XY | — | 9 | M | 86 | IR |
| 14048 | AML-M4 | 46, XX, t(9;11) | MLL-AF9 | 63 | F | 90 | HR |
| 14057 | AML-M5 | 46, XX | NPM1MUT, FLT3-ITDhi | 65 | F | 90 | HR |
| 14058 | AML-M1 | 46, XX | NPM1MUT, FLT3-ITDhi | 73 | F | 90 | HR |
| 14070 | AML-M1 | 46, XX, t(9;11) | MLL-AF9 | 77 | F | 80 | HR |
| 14085 | AML-M4 | 46, XY | NPM1MUT, FLT3-ITDhi, WT1MUT | 42 | M | 99 | HR |
| 14093 | AML-M4 | 46, XX | NPM1MUT, FLT3-ITDhi | 52 | F | 81 | HR |
| 14160 | AML-M5a | 47,XX,8,+i(8)(q10)x2,t(8;21),t(9;11) | MLL-AF9, ABL+, AML1-ETO, WT1MUT | 6 | F | 66 | HR |
| 14186 | AML-M5b | 46,XY,t(11;17) MLL (11q23)+ | MLL-RARa | 1 | M | 87 | HR |
| 14163 | AML | 46, XY | NPM1MUT, FLT3-ITDhi | 48 | M | 88 | HR |
F, female; FLT3-ITDhi, high FLT3-ITD allele burden; M, male; —, no mutation in TP53, FLT3, or NPM1.